Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

May 17, 2021

SELL
$29.24 - $42.03 $1.28 Million - $1.85 Million
-43,900 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $787,200 - $1.54 Million
20,000 Added 83.68%
43,900 $1.73 Million
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $1.26 Million - $1.96 Million
23,900 New
23,900 $1.87 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $362M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.